SapientA leading biomarker discovery organization providing large-scale services for multi-omics data generation and analysis has announced a partnership with. Rancho Bioscienceis a provider of best-in-class life sciences data curation services and the next generation Intelligent human biology database. This in-house database already consists of metabolomics, lipidomics, proteomics, and genomic measurements collected from more than 100,000 human biological samples and more than 130 million paired phenotypic data points, which Sapient We use it in client projects to verify and mine biomarkers. , identify drug targets and derive biological insights that inform drug development decisions. Building on this foundation, Rancho supports infrastructure expansion to accelerate the ingestion of additional multi-omics and real-world data, homogenize new and existing datasets, and expand the breadth and multidimensional insights it can provide. Expand the depth further.
“We believe that integrated multi-omics data will play a key role in future drug development, and will continue to explore how different molecular interactions impact disease in order to enable better subtyping and drug targeting. “We strongly believe that we will find out what we want to do,” said Tao Long, Co-Founder and Head of Data Science. In Sapient. “We are investing in this future by working with Rancho on next-generation databases. We are creating a path to efficiently add more types of omics data, including atomic and genomic measurements. Ultimately, this will increase the speed, versatility, and depth of analysis we can offer to our clients. Improve your data insights.”
To support the project, Rancho will deploy subject matter experts (SMEs) who are experts in curating a variety of internal and public life science datasets, including clinical trials, patient health records, and genomics. Julie Bryant, Founder and CEO of Rancho BioSciences, said: “Rancho’s expertise and strategic use of AI will accelerate the growth of the human biology database and increase the speed and impact of Sapient’s data analysis.Rancho will accelerate drug development through technology enablement and high-quality data. continues to set the standard for multi-omics data integration that delivers tangible value.”
“We chose Rancho as our partner not only because we found them to be best-in-class in terms of data engineering capabilities, but also because of their deep expertise in clinical data ontology,” said Jamie Cho, Head of Software Engineering. said. In Sapient. “Their understanding of real-world data architectures and our expertise in processing different types of omics data will enable the next evolution of our database and support the future of delivering insights to our customers. It’s the perfect combination.”
